

| | | | | | |
|--|---|----|---|--------------------------|-------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | 4037 |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Sudhaker B. Patel |
| Sheet | 1 | of | 2 | Attorney Docket No. | PHA 2011.1 (3167/5Z/US) |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| <i>[Signature]</i> | 209. | 6,087,392 | | Reiter | 07-11-2000 |
| <i>[Signature]</i> | 210. | 6,110,964 | | Robinson | 08-29-2000 |
| <i>[Signature]</i> | 211. | 6,114,361 | | Robinson et al. | 09-05-2000 |
| <i>[Signature]</i> | 212. | 6,156,798 | | Reiter | 12-05-2000 |
| <i>[Signature]</i> | 213. | 6,214,870 | B1 | McClure et al. | 04-10-2001 |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| <i>[Signature]</i> | 214. | EP | 1 081 137 | A1 | Pfizer Products Inc. | 03-07-2001 | ✓ |
| <i>[Signature]</i> | 215. | EP | 1 088 550 | A1 | Pfizer Products Inc. | 04-04-2001 | ✓ |
| <i>[Signature]</i> | 216. | EP | 1 134 215 | A1 | Pfizer Products Inc. | 09-19-2001 | ✓ |
| <i>[Signature]</i> | 217. | EP | 1 138 680 | A1 | Pfizer Products Inc. | 10-04-2001 | ✓ |
| <i>[Signature]</i> | 218. | WO | 98/03516 | A1 | Pfizer Inc. | 01-29-1998 | ✓ |
| <i>[Signature]</i> | 219. | WO | 98/16227 | A1 | G.D. Searle & Co. | 04-23-1998 | ✓ |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 3/15/04 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

JAN 21 2004

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

JAN 21 2004

Sheet 2 of 2


Complete if Known

| | |
|----------------------|-------------------------|
| Application Number | 09/857,995 |
| Filing Date | October 5, 2001 |
| Confirmation Number | 4037 |
| First Named Inventor | John P. McKearn et al. |
| Group Art Unit | 1624 |
| Examiner Name | Sudhaker B. Patel |
| Attorney Docket No. | PHA 2011.1 (3167/5Z/US) |

| | | | | | | |
|------|----|----------|----|----------------------|------------|--|
| 220. | WO | 98/22101 | A3 | G.D. Searle & Co. | 05-28-1998 | |
| 221. | WO | 98/30566 | A1 | Pfizer Inc. | 07-16-1998 | |
| 222. | WO | 98/47890 | A1 | G.D. Searle & Co. | 10-29-1998 | |
| 223. | WO | 00/09485 | A1 | Pfizer Products Inc. | 02-24-2000 | |
| 224. | WO | 00/09492 | A1 | Pfizer Products Inc. | 02-24-2000 | |
| 225. | WO | 00/73294 | A2 | Pfizer Products Inc. | 12-07-2000 | |
| 226. | WO | 01/12611 | A1 | Pfizer Products Inc. | 02-22-2001 | |
| 227. | WO | 01/40216 | A1 | Pfizer Products Inc. | 06-07-2001 | |

OTHER ART - NON PATENT LITERATURE DOCUMENTS


| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
|-----------------------|--------------------------|--|----------------|
| | | | |

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner Signature |  | Date Considered | 3/10/04 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



08-18-03

1624

#24

3

| | | | | | |
|--|---|----|----|----------------------------|--------------------------|
| PTO/SB/08A AUG 15 2003 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Completion if Known | |
| | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearney et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 1 | of | 15 | Attorney Docket No. | PHA 4294 (3167/52) |

RECEIVED
AUG 20 2001
TECHNICAL UNIT

RECEIVED

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|----------------------|--------------------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
| | | Number | Kind Code ² (if known) | | |
| <i>[initials]</i> | 1. | 4,100,274 | | Dutta et al. | 07-11-1978 |
| <i>[initials]</i> | 2. | 4,105,681 | | Bollag et al. | 08-08-1978 |
| <i>[initials]</i> | 3. | 4,140,707 | | Cleare et al. | 02-20-1979 |
| <i>[initials]</i> | 4. | 4,215,215 | | Bollag et al. | 07-29-1980 |
| <i>[initials]</i> | 5. | 4,310,666 | | Zee-Cheng et al. | 01-12-1982 |
| <i>[initials]</i> | 6. | 4,472,382 | | Labrie et al. | 09-18-1984 |
| <i>[initials]</i> | 7. | 4,596,797 | | Schweikert et al. | 06-24-1986 |
| <i>[initials]</i> | 8. | 5,250,683 | | Holton et al. | 10-05-1993 |
| <i>[initials]</i> | 9. | 5,254,703 | | Holton | 10-19-1993 |
| <i>[initials]</i> | 10. | 5,272,171 | | Ueda et al. | 12-21-1993 |
| <i>[initials]</i> | 11. | 5,319,112 | | Kingston et al. | 06-07-1994 |
| <i>[initials]</i> | 12. | 5,344,991 | | Reitz et al. | 09-06-1994 |
| <i>[initials]</i> | 13. | 5,455,270 | | Kaplan et al. | 10-03-1995 |
| <i>[initials]</i> | 14. | 5,633,016 | | Johnson | 05-27-1997 |
| <i>[initials]</i> | 15. | 5,672,583 | | Chapman et al. | 09-30-1997 |
| <i>[initials]</i> | 16. | 5,686,419 | | Powers et al. | 11-11-1997 |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 3/19/04 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

| | | | | | |
|---|---|----|----|--------------------------|-----------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKern et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 2 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|-----|-----------|----------------|------------|
| 17. | 5,696,131 | Baguley et al. | 12-09-1997 |
| 18. | 5,733,909 | Black et al. | 03-31-1998 |
| 19. | 5,767,142 | LaVoie et al. | 06-16-1998 |
| 20. | 5,824,699 | Kreft et al. | 10-20-1998 |
| 21. | 5,837,696 | Golub et al. | 11-17-1998 |
| 22. | 5,869,524 | Failli | 02-09-1999 |
| 23. | 5,952,381 | Chen et al. | 09-14-1999 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ² |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|----------------|
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| | 24. | DE | 195 48 798 | A1 | Dr. Karl Thomae GmbH | 07-03-1997 | A |
| | 25. | DE | 196 13 933 | A1 | Merck Patent GmbH | 10-09-1997 | A |
| | 26. | DE | 196 26 701 | A1 | Hoechst AG | 01-08-1998 | A |
| | 27. | EP | 0 010 458 | A1 | ANVAR | 04-30-1980 | A |
| | 28. | EP | 0 054 168 | A1 | Klinge Pharma GmbH & Co. | 06-23-1982 | A |
| | 29. | EP | 0 095 875 | A2 | Farnos Group Ltd. | 12-07-1983 | |
| | 30. | EP | 0 165 904 | A2 | Ciba-Geigy AG | 12-27-1985 | A |
| | 31. | EP | 0 199 636 | A1 | C.I.R.D. | 10-29-1986 | A |
| | 32. | EP | 0 236 940 | B1 | Ciba-Geigy AG | 09-16-1987 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 3/15/04 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
AUG 10 2003
TECH CENTER
60012500

COPIES
AUG 15 2003
PATENT & TRADEMARK OFFICE

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 3 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | | | | |
|----------------|---------------|----------------------|---------------|---|-----------------------|--------------|
| 33. | EP | 0 260 744 | B1 | Janssen Pharmaceutica N.V. | 03-23-1988 | |
| 34. | EP | 0 299 402 | A2 | ASTA Pharma Aktiengesellschaft | 01-18-1989 | A |
| 35. | EP | 0 331 983 | A2 | F. Hoffmann-La Roche AG | 09-13-1989 | A |
| 36. | EP | 0 402 232 | A1 | Rhone-Poulenc Sante | 12-12-1990 | A |
| 37. | EP | 0 532 156 | A1 | Matsuno et al. | 03-17-1993 | |
| 38. | EP | 0 579 915 | A1 | F. Hoffmann-La Roche AG | 01-26-1994 | A |
| 39. | EP | 0 640 594 | A1 | Fujirebio Inc. | 03-01-1995 | |
| 40. | EP | 0 702 962 | A2 | Eli Lilly and Company | 03-27-1996 | |
| 41. | EP | 0 703 239 | A1 | Hoechst Aktiengesellschaft | 03-27-1996 | A |
| 42. | EP | 0 716 086 | A1 | Boehringer Mannheim GMBH | 06-12-1996 | |
| 43. | EP | 0 743 070 | A2 | Trnka Mudr et al. | 11-20-1996 | A |
| 44. | EP | 0 758 649 | A1 | Kureha Chemical Industry Co., Ltd. | 02-19-1997 | |
| 45. | EP | 0 818 443 | A2 | American Cyanamid Company | 01-14-1998 | |
| 46. | EP | 0 882 734 | A2 | F. Hoffman-La Roche AG | 12-09-1998 | |
| 47. | EP | 0 921 119 | A1 | ADIR Et Compagnie | 06-09-1999 | A |
| 48. | GB | 2 282 598 | A | Merck & Co., Inc. | 04-12-1995 | |
| 49. | WO | 87/07609 | A1 | Taiho Pharmaceutical Co., Ltd. | 12-17-1987 | A |
| 50. | WO | 93/00427 | A2 | Erziehungsdirektion of the Canton Zurich | 01-07-1993 | |
| 51. | WO | 93/11145 | A1 | Banyu Pharmaceutical Co., Ltd. | 06-10-1993 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 3/10/04 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

6
RECEIVED

TECH CENTER 1600/2900
AUG 2 10 2003

| | | | | | |
|---|---|----|----|----------------------|------------------------|
| PTO/SB/08A | | | | Compl te if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 4 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | | | | | |
|----------|-----|----|----------|----|--|------------|--|
| <i>h</i> | 52. | WO | 93/18652 | A1 | Merck & Co. | 09-30-1993 | |
| <i>h</i> | 53. | WO | 94/02466 | A1 | The Du Pont Merck Pharmaceutical Company | 02-03-1994 | |
| <i>h</i> | 54. | WO | 94/12169 | A1 | Merck & Co., Inc. | 06-09-1994 | |
| <i>h</i> | 55. | WO | 94/13635 | A1 | Merck Frosst Canada Inc. | 06-23-1994 | |
| <i>h</i> | 56. | WO | 94/20480 | A1 | Merck Frosst Canada Inc. | 09-15-1994 | |
| <i>h</i> | 57. | WO | 94/21612 | A1 | Otsuka Pharmaceutical Co., Ltd. | 09-29-1994 | |
| <i>h</i> | 58. | WO | 94/25431 | A1 | The Wellcome Foundation Limited | 11-10-1994 | |
| <i>h</i> | 59. | WO | 94/25466 | A1 | Glaxo, Inc. | 11-10-1994 | |
| <i>h</i> | 60. | WO | 94/26731 | A1 | Merck Frosst Canada Inc. | 11-24-1994 | |
| <i>h</i> | 61. | WO | 94/27980 | A1 | G.D. Searle & Co. | 12-08-1994 | |
| <i>h</i> | 62. | WO | 95/02603 | A2 | Pharmacia S.P.A. | 01-26-1995 | |
| <i>h</i> | 63. | WO | 95/08327 | A1 | The Government of the United States of America | 03-30-1995 | |
| <i>h</i> | 64. | WO | 95/11883 | A1 | G.D. Searle & Co. | 05-04-1995 | |
| <i>h</i> | 65. | WO | 95/12606 | A1 | The Wellcome Foundation Limited | 05-11-1995 | |
| <i>h</i> | 66. | WO | 95/13289 | A1 | Chiroscience Limited | 05-18-1995 | |
| <i>h</i> | 67. | WO | 95/15316 | A1 | G.D. Searle & Co. | 06-08-1995 | |
| <i>h</i> | 68. | WO | 95/24199 | A2 | Cell Therapeutics, Inc. | 09-14-1995 | |
| <i>h</i> | 69. | WO | 95/29892 | A1 | The Du Pont Merck Pharmaceutical Company | 11-09-1995 | |
| <i>h</i> | 70. | WO | 95/30652 | A1 | G.D. Searle & Co. | 11-16-1995 | |

| | | | |
|--------------------|----------|-----------------|---------|
| Examiner Signature | <i>h</i> | Date Considered | 3/10/04 |
|--------------------|----------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/857,995
 Filing Date October 5, 2000
 Confirmation Number Unknown
 First Named Inventor John P. McKearn et al.
 Group Art Unit 1624
 Examiner Name Unknown
 Attorney Docket No. PHA 4294 (3167/5Z)


Sheet

5

of

15

| | | | | | |
|-----|----|----------|----|---|------------|
| 71. | WO | 95/30656 | A1 | G.D. Searle & Co. | 11-16-1995 |
| 72. | WO | 96/00214 | A1 | Ciba-Geigy AG | 01-04-1996 |
| 73. | WO | 96/00574 | A1 | Smithkline Beecham Corporation | 01-11-1996 |
| 74. | WO | 96/01653 | A1 | Board of Regents, The University of Texas System et al. | 01-25-1996 |
| 75. | WO | 96/03387 | A1 | G.D. Searle & Co. | 02-08-1996 |
| 76. | WO | 96/03392 | A1 | G.D. Searle & Co. | 02-08-1996 |
| 77. | WO | 96/06840 | A1 | Merck Frosst Canada Inc. | 03-07-1996 |
| 78. | WO | 96/14745 | A1 | The Regents of the University of California | 05-23-1996 |
| 79. | WO | 96/15096 | A1 | Bayer Corporation | 05-23-1996 |
| 80. | WO | 96/21667 | A1 | Merck Frosst Canada Inc. | 07-18-1996 |
| 81. | WO | 96/23791 | A1 | Syntex Inc. | 08-08-1996 |
| 82. | WO | 96/27583 | A1 | Pfizer Inc. | 09-12-1996 |
| 83. | WO | 96/33988 | A1 | Wisconsin Alumni Research Foundation | 10-31-1996 |
| 84. | WO | 96/35774 | A2 | The Children's Medical Center Corporation | 11-14-1996 |
| 85. | WO | 96/36335 | A1 | Pharmacia S.P.A. | 11-21-1996 |
| 86. | WO | 96/36612 | A1 | Rutgers, The State University of New Jersey | 11-21-1996 |
| 87. | WO | 96/36622 | A1 | Indena S.P.A. | 11-21-1996 |
| 88. | WO | 96/36623 | A1 | Merck Frosst Canada Inc. | 11-21-1996 |

Examiner
Signature

Date
Considered

3/10/01

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED

AUG 20 2003
TECH CENTER 1600/2900

PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | |
|----------------------|------------------------|
| Application Number | 09/857,995 |
| Filing Date | October 5, 2001 |
| Confirmation Number | Unknown |
| First Named Inventor | John P. McKearn et al. |
| Group Art Unit | 1624 |
| Examiner Name | Unknown |

| | | | | | |
|-------|---|----|----|---------------------|--------------------|
| Sheet | 6 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |
|-------|---|----|----|---------------------|--------------------|

| | | | | | | | |
|-----------|------|----|----------|----|--|------------|--|
| <i>bc</i> | 89. | WO | 96/37469 | A1 | Merck Frosst Canada Inc. | 11-28-1996 | |
| <i>bc</i> | 90. | WO | 97/11693 | A1 | 3-Dimensional Pharmaceuticals, Inc. | 04-03-1997 | |
| <i>bc</i> | 91. | WO | 97/15666 | A1 | The Children's Medical Center Corporation | 05-01-1997 | |
| <i>bc</i> | 92. | WO | 97/15676 | A2 | Abbott Laboratories | 05-01-1997 | |
| <i>bc</i> | 93. | WO | 97/19068 | A1 | Warner-Lambert Company | 05-29-1997 | |
| <i>bc</i> | 94. | WO | 97/19954 | A1 | Asta Medica Aktiengesellschaft | 06-05-1997 | |
| <i>bc</i> | 95. | WO | 97/20835 | A1 | Harbor Branch Oceanographic Institution, Inc. | 06-12-1997 | |
| <i>bc</i> | 96. | WO | 97/23459 | A1 | Warner-Lambert Company | 07-03-1997 | |
| <i>bc</i> | 97. | WO | 97/24116 | A2 | Allergan | 07-10-1997 | |
| <i>bc</i> | 98. | WO | 97/29106 | A1 | Rutgers, The State University of New Jersey | 08-14-1997 | |
| <i>bc</i> | 99. | WO | 97/31936 | A2 | Wisconsin Alumni Research Foundation | 09-04-1997 | |
| <i>bc</i> | 100. | WO | 97/34608 | A1 | Mayo Foundation for Medical Education and Research | 09-25-1997 | |
| <i>bc</i> | 101. | WO | 97/36497 | A2 | Mars, Incorporated | 10-09-1997 | |
| <i>bc</i> | 102. | WO | 97/36863 | A1 | Merck Frosst Canada Inc. | 10-09-1997 | |
| <i>bc</i> | 103. | WO | 97/37658 | A1 | Boehringer Mannheim Italia S.P.A. | 10-16-1997 | |
| <i>bc</i> | 104. | WO | 97/41844 | A1 | Alcon Laboratories, Inc. | 11-13-1997 | |
| <i>bc</i> | 105. | WO | 97/44315 | A1 | Warner-Lambert Company | 11-27-1997 | |

Examiner
Signature*James B. B. B.*Date
Considered

3/10/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
 AUG 21 2003
 TECH CENTER 1600/2900

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2000 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 7 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

OFFICE OF
 PATENT & TRADEMARKS
 AUG 15 2003

| | | | | | | |
|-----------------|----|----------|----|---|------------|---|
| 106. | WO | 97/47296 | A2 | Mount Sinai Hospital Corporation | 12-18-1997 | |
| 107. | WO | 97/47599 | A1 | Fujisawa Pharmaceutical Co., Ltd. | 12-18-1997 | |
| 108. | WO | 97/48685 | A1 | Glaxo Group Limited | 12-24-1997 | |
| 109. | WO | 97/49704 | A1 | Janssen Pharmaceutica N.V. | 12-31-1997 | |
| 110. | WO | 98/03166 | A1 | Monsanto Company | 01-29-1998 | |
| 111. | WO | 98/03484 | A1 | Merck Frosst Canada Inc. | 01-29-1998 | |
| 112. | WO | 98/05635 | A1 | Chiroscience Limited | 02-12-1998 | |
| 113. | WO | 98/07433 | A1 | Bristol-Myers Squibb Company | 02-26-1998 | |
| 114. | WO | 98/08814 | A1 | The Procter & Gamble Company | 03-05-1998 | |
| 115. | WO | 98/08850 | A1 | The Procter & Gamble Company | 03-05-1998 | |
| 116. | WO | 98/12181 | A1 | Rutgers, The State University of New Jersey | 03-26-1998 | |
| 117. | WO | 98/13350 | A1 | Zeneca Limited | 04-02-1998 | |
| 118. | WO | 98/14188 | A1 | Ilex Oncology Inc. | 04-09-1998 | |
| 119. | WO | 98/15525 | A1 | Sumitomo Pharmaceuticals Co., Ltd. | 04-16-1998 | A |
| 120. | WO | 98/16227 | A1 | G.D. Searle & Co. | 04-23-1998 | |
| 121. | WO | 98/22101 | A2 | G.D. Searle & Co. | 05-28-1998 | |
| 122. | WO | 98/25603 | A1 | Ilex Oncology, Inc. | 06-18-1998 | |
| 123. | WO | 98/25896 | A1 | G.D. Searle & Co. | 06-18-1998 | |
| 124. | WO | 98/27069 | A1 | Fujisawa Pharmaceutical Co., Ltd. | 06-25-1998 | |

| | | | |
|--------------------|---------------------|-----------------|--------|
| Examiner Signature | <i>James B. ...</i> | Date Considered | 3/1/04 |
|--------------------|---------------------|-----------------|--------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
AUG 20 2003
TECH CENTER 1600129005

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 8 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | | | | | |
|-------------------|------|----|----------|----|---|------------|--|
| <i>[initials]</i> | 125. | WO | 98/33768 | A1 | Pfizer Products, Inc. | 08-06-1998 | |
| <i>[initials]</i> | 126. | WO | 98/33788 | A1 | Pharmacia & Upjohn S.P.A. | 08-06-1998 | |
| <i>[initials]</i> | 127. | WO | 98/40104 | A2 | Yale University et al. | 09-17-1998 | |
| <i>[initials]</i> | 128. | WO | 98/45294 | A1 | Astra Pharmaceuticals Ltd. | 10-15-1998 | |
| <i>[initials]</i> | 129. | WO | 99/01131 | A1 | Smithkline Beecham Corporation | 01-14-1999 | |
| <i>[initials]</i> | 130. | WO | 99/05104 | A1 | Pfizer Pharmaceuticals Inc. | 02-04-1999 | |
| <i>[initials]</i> | 131. | WO | 99/10331 | A1 | Abbott Laboratories | 03-04-1999 | |
| <i>[initials]</i> | 132. | WO | 99/12930 | A1 | Glaxo Group Limited | 03-18-1999 | |
| <i>[initials]</i> | 133. | WO | 99/14194 | A1 | Merck Frosst Canada Inc. | 03-25-1999 | |
| <i>[initials]</i> | 134. | WO | 99/14205 | A1 | Almirall Prodesfarma S.A. | 03-25-1999 | |
| <i>[initials]</i> | 135. | WO | 99/21583 | A1 | Warner-Lambert Company | 05-06-1999 | |
| <i>[initials]</i> | 136. | WO | 99/23087 | A1 | Merck Frosst Canada & Co. | 05-14-1999 | |
| <i>[initials]</i> | 137. | WO | 99/31067 | A1 | Rutgers, The State University of New Jersey | 06-24-1999 | |
| <i>[initials]</i> | 138. | WO | 99/41241 | A1 | Rutgers, The State University of New Jersey | 08-19-1999 | |

OTHER ART - NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|--------------------|-----------------------|--|----------------|
| <i>[initials]</i> | 139. | BARNI, S., et al., Clinical Efficacy of the Aromatase Inhibitor Anastrozole in Relation to Prolactin Secretion in Heavily Pretreated Metastatic Breast Cancer, Tumour, Jan.-Feb. 1998, pp. 45-47, Vol. 84(1) | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 3/10/04 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
AUG 2 2003
TECH CENTER 1600/2400

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2000 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 9 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|--|------|---|--|
| | 140. | BENSON, J.R., et al., Tamoxifen, Biologic Therapy of Cancer: Principles and Practice, 1997, pp. 817-828, Vol. One, Ch. 29, J.F. Holland et al. (Eds.), Baltimore, MD | |
| | 141. | BREMBECK, F.H., et al., A Phase II Pilot Trial of 13-cis Retinoic Acid and Interferon- α in UICC Stage III/IV Pancreatic Cancer, Gastroenterology Oncology, April 1998, Abstract G2329, Vol. 114, No. 4, Pt. 2, A569 | |
| | 142. | BREMBECK, F.H., et al., A Phase II Trial of 13-cis Retinoic Acid and Interferon- α in Patients with Advanced Pancreatic Carcinoma, Cancer, 1998, pp. 2317-2323, Vol. 83, No. 11 | |
| | 143. | BROOKS, P.C., et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, Cell, Dec. 30, 1994, pp. 1157-1164, Vol. 79 | |
| | 144. | BROWN, F.K., et al., Matrix Metalloproteinase Inhibitors Containing a (Carboxyalkyl)amino Zinc Ligand: Modification of the P1 and P2' Residues, J. Med. Chem., 1994, pp. 674-688, Vol. 37 | |
| | 145. | CAO, Y., et al., Kringle Domains of Human Angiostatin, The Journal of Biological Chemistry, Nov. 15, 1996, pp. 29461-29467, Vol. 271, No. 46 | |
| | 146. | CHERNEY, R.J., et al., Macrocyclic Amino Carboxylates as Selective MMP-8 Inhibitors, J. Med. Chem., 1998, pp. 1749-1751, Vol. 41 | |
| | 147. | DENIS, L.J., et al., Matrix metalloproteinase inhibitors: Present achievements and future prospects, Investigational New Drugs, 1997, pp. 175-185, Vol. 15 | |
| | 148. | DONG, Z., et al., Macrophage-Derived Metalloelastase is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma, Cell, Mar. 21, 1997, pp. 801-810, Vol. 88 | |
| | 149. | DRUMMOND, A.H., et al., Preclinical and Clinical Studies of MMP Inhibitors in Cancer, Annals of the New York Academy of Science, June 1999, pp. 228-235, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |
| | 150. | DURANDO, A., et al., Combination chemotherapy with paclitaxel (T) and epirubicin (E) for metastatic breast cancer (MBC): A phase I-II study, European Journal of Cancer, Sept. 30, 1998, pp. S12-13, Abstract 41 | |
| | 151. | FAN, T.-P.D., et al., Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy, Trends Pharmacol.Sci. Feb. 1995, pp. 57-66, Vol. 16 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 3/09/04 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608... Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
 AUG 2 3 2003
 TECH CENTER 160019900

12

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 10 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|--------------------|------|---|--|
| <i>[Signature]</i> | 152. | FISHER, J.E., et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, An, "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, Endocrinology, 1993, pp. 1411-1413, Vol. 132, No. 3 | |
| <i>[Signature]</i> | 153. | FORMENTI, C., et al., Concurrent paclitaxel and radiation in locally advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S12, Abstract 39 | |
| <i>[Signature]</i> | 154. | GALARDY, R.E., et al., Inhibition of Angiogenesis by the Matrix Metalloprotease Inhibitor N-[2R-2-(Hydroxamidocarbonylmethyl)-4-methylpentanoyl]-L-tryptophan Methylamide, Cancer Research, Sept. 1, 1994, pp. 4715-4718, Vol. 54 | |
| <i>[Signature]</i> | 155. | GEARING, A.J.H., et al., Processing of tumour necrosis factor- α precursor by metalloproteinases, Letters to Nature, Aug. 18, 1994, pp. 555-557, Vol. 370 | |
| <i>[Signature]</i> | 156. | GIANNIS, A., et al., Integrin Antagonists and Other Low Molecular Weight Compounds as Inhibitors of Angiogenesis: New Drugs in Cancer Therapy, Angew. Chem. Int. Ed. Engl., 1997, pp 588-590, Vol. 36, No. 6 | |
| <i>[Signature]</i> | 157. | GUTTERMAN, J.U., Cytokine Therapeutics: Lessons from interferon α , Proc. Natl. Acad. Sci., USA, Feb. 1994, pp. 1198-1205, Vol. 91 | |
| <i>[Signature]</i> | 158. | HANDSCHUMACHER, R.E., et al., Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 712-732, Ch. XV1-2, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers | |
| <i>[Signature]</i> | 159. | IHDE, D.C., M.D., Current Status of Therapy for Small Cell Carcinoma of the Lung, Cancer, Dec. 1, 1984 Supplement, pp. 2722-2728, Vol. 54 | |
| <i>[Signature]</i> | 160. | International Search Report for Application No. PCT/US99/30699, dated July 21, 2000 | |
| <i>[Signature]</i> | 161. | JACOBSON, I.C., et al., Structure-Based Design and Synthesis of a Series of Hydroxamic Acids with a Quaternary-Hydroxy Group in P1 as Inhibitors of Matrix Metalloproteinases, Bio-Organic & Medicinal Chemistry Letters, 1998, pp. 837-842, Vol. 8 | |
| <i>[Signature]</i> | 162. | JAYSON, G.C., ET AL., A randomized phase II trial of interleukin 2 and interleukin 2-interferon alpha in advanced renal cancer, British Journal of Cancer, 1998, pp. 366-369, Vol. 78(3) | |
| <i>[Signature]</i> | 163. | JOSS, R.A., et al., New agents in non-small cell lung cancer, Cancer Treatment Reviews, 1984, pp. 205-236, Vol.11 | |

| | | | |
|--------------------|--------------------|-----------------|---------|
| Examiner Signature | <i>[Signature]</i> | Date Considered | 3/15/04 |
|--------------------|--------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

RECEIVED
AUG 20 2003
TECH. CENTER 1600/2300

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 11 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|--|------|---|--|
| | 164. | KROWN, S.E., The Role of Interferon in the Therapy of Epidemic Kaposi's Sarcoma, Seminars in Oncology, June, 1987, pp.27-33, Vol. 14, No. 2, Suppl. 3 | |
| | 165. | LARK, M.W., et al., <i>In Vivo</i> Activity of Human Recombinant Tissue Inhibitor of Metalloproteinases (TIMP), Biochem Pharmacol, 1990, pp. 2041-2049, Vol. 39, No. 12 | |
| | 166. | LINGEN, M.W., et al., Retinoic Acid and Interferon α Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma, Cancer Research, Dec. 1, 1998, pp. 5551-5558, Vol. 58 | |
| | 167. | LODE, H.N., et al., Synergy between an antiangiogenic integrin α , antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, Proc. Nat. Acad. Sci. USA., Feb. 1999, pp. 1591-1596, Vol. 96 | |
| | 168. | LOKESHWAR, B.L, MMP Inhibition in Prostate Cancer, Annals of the New York Academy of Science, June 1999, pp. 271-289, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |
| | 169. | MACKEAN, M.J., et al., A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma, British Journal of Cancer, 1998, pp. 1620-1623, Vol. 78(12) | |
| | 170. | MAIONE, T.E., et al., Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptides, Science, Jan. 5, 1990, pp. 77-79, Vol. 247 | |
| | 171. | MAJEWSKI, S., et al., Synergistic Anticancer Action of Retinoids, Vitamin D3 and Cytokines (Interferons and Interleukin-12) as Related to the Antiangiogenic and Antiproliferative Effects, J.Invest.Dermatol., April 1997, Abstract 202, Vol. 108, No. 4 | |
| | 172. | McGEEHAN, G.M., et al., Regulation of tumor necrosis factor- α processing by a metalloproteinase inhibitor, Letters to Nature, Aug. 18, 1994, pp. 558-561, Vol. 370 | |
| | 173. | MONTGOMERY, A.M.P., et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, Proc. Natl. Acad. Sci. USA, Sept. 1994, pp. 8856-8860, Vol. 91 | |
| | 174. | MOON, R.C., et al., N-(4-Hydroxyphenyl)retinamide, A New Retinoid for Prevention of Breast Cancer in the Rat, Cancer Research, April 1979, pp. 1339-1346, Vol. 39 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 3/10/04 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

14
 RECEIVED
 AUG 20 2003
 TECH CENTER 1600/2900

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 12 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|-----|------|---|--|
| 828 | 175. | MORIMOTO, Y., et al., KB-R7785, A Novel Matrix Metalloproteinase Inhibitor, Exerts Its Antidiabetic Effect By Inhibiting Tumor Necrosis Factor- α Production, Life Sciences, 1997, pp. 795-803, Vol. 61, No. 8 | |
| 828 | 176. | MÜLLER, H., Antio-genesis-inhibition and intra-arterial chemotherapy - A new modality treatment for advanced and metastatic pancreatic carcinoma, Eur.J.Cancer 33, 1997, Abstract 215, p. S50, Suppl. 8 | |
| 828 | 177. | NAITO, K., et al., Inhibition of Growth of Human Tumor Cells in Nude Mice by a Metalloproteinase Inhibitor, Int. J. Cancer, 1994, pp. 730-735, Vol 58 | |
| 828 | 178. | NERI, A., et al., Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice, Proceedings of the American Association for Cancer Research, Mar. 1998, p. 302, Abstract 2060, Vol. 39 | |
| 828 | 179. | O'REILLY, M.S., et al., Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth, Cell, Jan. 24, 1997, pp. 277-285, Vol. 88 | |
| 828 | 180. | OSAKI, A., et al., A combination therapy with mitomycin-C, etoposide, doxorubicin and medroxyprogesterone acetate as second-line therapy for advanced breast cancer, European Journal of Cancer, Sept. 30, 1998, p. S16, Abstract 56 | |
| 828 | 181. | PFAFF, M., et al., Selective Recognition of Cyclic RGD Peptides of NMR Defined Conformation by α IIb β 3, α V β 3, and α 5 β 1 Integrins, The Journal of Biological Chemistry, Aug. 12, 1994, pp. 20233-20238, Vol. 269, No. 32 | |
| 828 | 182. | POWLES, T.J., II.1 Tamoxifen's Oestrogen-like Effects in a Breast Cancer Chemoprevention Trial, European Journal of Cancer, 1998, pp. S17-S18, Vol. 34, Suppl. 4, printed in Great Britain | |
| 828 | 183. | PRATT, L.M., et al., Bioorganic Medicinal Chemistry Letters, 1998, pp. 1359-1364, Vol. 8 | |
| 828 | 184. | RASMUSSEN, H.S., et al., Matrix Metalloproteinase Inhibition as a Novel Anticancer Strategy: A Review with Special Focus on Batimastat and Marimastat, Pharmacol. Ther., 1997, pp. 69-75, Vol. 75, No. 1 | |
| 828 | 185. | RAVAUD, A., et al., Subcutaneous Interleukin-2, Interferon Alfa-2a, and Continuous Infusion of Fluorouracil in Metastatic Renal Cell Carcinoma: A Multicenter Phase II Trial, Journal of Clinical Oncology, Aug. 1998, pp. 2728, 2732, Vol. 16, No. 8 | |

| | | | |
|--------------------|--------------------------------|-----------------|---------|
| Examiner Signature | <i>Sudhakar B. [Signature]</i> | Date Considered | 3/10/02 |
|--------------------|--------------------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.











¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

15
RECEIVED

AUG 2 2003
TECH. CENTER 1600/2900

| | | | | | |
|---|----|----|----|----------------------|------------------------|
| PTO/SB/08A | | | | Compl te if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 13 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|---|------|---|--|
|  | 186. | ROSENBERG, S.A., et al., Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, Journal of Clinical Oncology, Mar. 1999, pp. 968-975, Vol. 17, No. 3 | |
|  | 187. | RYAN, C.W., et al., A Phase II Trial of Outpatient Subcutaneous GM-CSF, Interleukin-2, and Interferon-Alpha Plus Oral cis-Retinoic Acid in Patients with Metastatic Renal Cell Cancer, J.Invest.Med., 1998, p. 274A, Vol. 46, No. 7 | |
|  | 188. | SCHACHTER, J., et al., A Sequential Four-drug Chemotherapy and Biotherapy with Interferon Alpha and GM-CSF - An Innovative Protocol for the Treatment of Metastatic Melanoma, Cancer Biotherapy & Radiopharmaceuticals, 1998, pp. 155-164, Vol. 13, No. 3 | |
|  | 189. | SEFTOR, R.E.B., et al., Role of the $\alpha_5\beta_1$ integrin in human melanoma cell invasion, Proc. Natl. Acad. Sci. USA, Mar. 1992, pp. 1557-1561, Vol. 89 | |
|  | 190. | SHALINSKY, et al., Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials, Annals of the New York Academy of Science, June 1999, pp. 236-270, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |
|  | 191. | SILBER, R., et al., DNA Topoisomerase I Inhibitors, Purine and Pyrimidine Antimetabolites, Chemotherapeutic Agents, pp. 779-782, Ch. XV1-7, 3rd Edition, Edited by J. Holland, et al., Lea and Febigol, publishers | |
|  | 192. | SOORI, G.S., et al., Phase II Study of Chemo-Biotherapy with Chlorambucil and Alpha Interferon in Patients with Non-Hodgkin's Lymphoma (NHL), Abstract #4032, Blood, 1998, pp. 240b, Vol. 92, No. 10 | |
|  | 193. | STADLER, W.M., et al., Multicenter Phase II Trial of Interleukin-2, Interferon- α , and 13-cis-Retinoic Acid in Patients With Metastatic Renal-Cell Carcinoma, Journal of Clinical Oncology, May 1998, pp.1820-1825, Vol. 16, No. 5 | |
|  | 194. | STRAUSS, G.M., et al., Multimodality Treatment of Stage IIIA Non-Small-Cell Lung Carcinoma: A critical Review of the Literature and Strategies for Future Research, Journal of Clinical Oncology, May, 1992, pp. 829-838, Vol. 10, No. 5 | |
|  | 195. | SUH, N., et al., Novel Triterpenoids Suppress Inducible Nitric Oxide Synthase (iNOS) and Inducible Cyclooxygenase (COX-2) in Mouse Macrophages ¹ , Cancer Research, Feb. 15, 1998, pp. 717-723, Vol. 58 | |

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 3/16/04 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

16
RECEIVED

AUG 20 2003
ECH CENTER 1600/2900

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| PTO/SB/08A | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 09/857,995 |
| | | | | Filing Date | October 5, 2001 |
| | | | | Confirmation Number | Unknown |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1624 |
| | | | | Examiner Name | Unknown |
| Sheet | 14 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |

| | | | |
|--|------|---|---|
| | 196. | TAKADA, Y., et al., Structures and functions of integrins, Jikken Igaku, 1996, pp. 2317-2322, Vol. 14 (17), English Abstract from SciFinder, Nov. 29, 2001, p. 3 | A |
| | 197. | TEICHER, B.A., et al., Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma, Breast Cancer Research and Treatment, 1995, pp. 227-236, Vol. 36 | |
| | 198. | TEICHER, B.A., et al., TNP-470/Minocycline/Cytotoxic Therapy: A Systems Approach to Cancer Therapy, European Journal of Cancer, 1996, pp. 2461-2466, Vol. 32A, No. 14 | |
| | 199. | THOMAS, C.A., et al., High-Dose Methotrexate (HD-MTX) Monotherapy in Patients with CNS Non-Hodgkin's Lymphoma, Blood, 1998, Abstract #4033, pp. 240b, Vol. 92, No. 10 | |
| | 200. | TOLSMA, S.S., et al., Peptides Derived from Two Separate Domains of the Matrix Protein Thrombospondin-1 Have Anti-Angiogenic Activity, The Journal of Cell Biology, 1993, pp. 497-511, Vol. 122 | |
| | 201. | TOURANI, J.-M., et al., Outpatient Treatment With Subcutaneous Interleukin-2 and Interferon Alfa Administration in Combination With Fluorouracil in Patients With Metastatic Renal Cell Carcinoma: Results of a Sequential Nonrandomized Phase II Study, Journal of Clinical Oncology, July 1998, pp. 2505-2513, Vol. 16, No. 7 | |
| | 202. | TUSZYNSKI, G.P., et al., The role of thrombospondin-1 in tumor progression and angiogenesis, Bioessays, 1996, pp. 71-76, Vol. 18, No. 1 | |
| | 203. | VARNER, J.A., et al., Tumor Angiogenesis and the Role of Vascular Cell Integrin $\alpha\beta 3$, Impt. Adv. Onc., 1996, pp. 69-87 | |
| | 204. | VON ROEDERN, E.G., et al., Design and Synthesis of Malonic Acid-Based Inhibitors of Human Neutrophil Collagenase (MMP8), J. Med. Chem., 1998, pp. 339-345, Vol. 41 | |
| | 205. | XUE, C.-B., et al., Design and Synthesis of Cyclic Inhibitors of Matrix Metalloproteinases and TNF- α Production, J. Med. Chem, 1998, pp. 1745-1748, Vol. 41 | |
| | 206. | YEH, L.-A., et al., Inhibition of Metalloproteinase by Futoenone Derivatives, Bio-Organic & Medicinal Chemistry Letters, 1995, pp. 1637-1642, Vol. 5, No. 15 | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner Signature | | Date Considered | 3/10/04 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

17

RECEIVED
TECH CENTER
AUG 15 2003



PTO/SB/08A

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

| | | | | | |
|-------|----|----|----|---------------------|--------------------|
| Sheet | 15 | of | 15 | Attorney Docket No. | PHA 4294 (3167/5Z) |
|-------|----|----|----|---------------------|--------------------|

| | | | |
|---|------|---|--|
|  | 207. | ZUCKER, S., Experimental Models to Identify Antimetastatic Drugs: Are We There Yet?, A Position Paper, Annals of the New York Academy of Science, June 1999, pp. 208-211, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |
|  | 208. | ZUCKER, S., et al., Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues, Clinical and Experimental Applications, Annals of the New York Academy of Science, June 1999, pp. 212-227, Vol. 878, Robert A. Greenwald and Stanley Zucker (Eds.) | |

RECEIVED
AUG 20 2003
TECH CENTER 160012900

| | | | |
|--------------------|---|-----------------|---------|
| Examiner Signature |  | Date Considered | 3/10/02 |
|--------------------|---|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.